RxDoctor Payments Data

Stuart Fischer, MD

Internal Medicine · Bronx, NYNPI 1518935857

Payments from drug & device makers

$2,208in general payments, 2019–2025

Across 34 payments — averaging $64.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$1K
  • AstraZeneca$347
  • Avanir Pharmaceuticals, Inc.$225
  • Sunovion Pharmaceuticals Inc.$127
  • Otsuka America Pharmaceutical, Inc.$122
  • Medtronic$119
  • plus $108 from 4 others

What the payments were for

  • Food & beverage$2,208100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,208 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$226,395
Medicare patients
203
Services billed
1,846

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban158$47,920
VerzenioAbemaciclib11$44,781
JardianceEmpagliflozin93$29,313
TivicayDolutegravir Sodium12$13,271
EntrestoSacubitril/Valsartan29$10,282
Sevelamer Carbonate68$9,531
LokelmaSodium Zirconium Cyclosilicate24$8,743
TrulicityDulaglutide16$8,377
TradjentaLinagliptin22$6,972
JanuviaSitagliptin Phosphate20$5,742
AbrysvoRsv Vacc, Pref A And Pref B/Pf16$5,296
Breo ElliptaFluticasone/Vilanterol12$5,240
Atorvastatin Calcium504$5,239
Memantine Hcl128$4,396
Tamsulosin Hcl288$3,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio, Trulicity$20$53,15827 claims
AstraZenecaLokelma$347$8,74324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →